Clinically Significant Drug Interactions
description
Transcript of Clinically Significant Drug Interactions
Clinically Significant Drug Interactions
2
Drug Interaction Definition•A clinically meaningful alteration in the effect of one
drug as a result of coadministration of another
•Drug affected by interaction is called the “object drug”
•Drug causing interaction is called the “precipitant drug”
• Interactions may be desirable or undesirable
3
Types of Drug Interactions•Drug-drug•Drug-disease•Drug-herbal•Drug-alcohol•Drug-food•Drug-nutritional status•Drug-lab
4
Mechanisms of Drug Interactions•Pharmacokinetic interactions ▫Percipitant drug affects the absorption, distribution,
metabolism, or excretion of object drug
•Pharmacodynamic interactions▫Effect of object drug is modified by the precipitant without
changes in pharmacokinetics of object drug
5
Pharmacokinetic Drug InteractionsA. Inhibition of Absorption
Mechanism Examples
Drug binding in GIT Iron may chelate ciprofloxacin, resulting in decreased absorption
GI motility Increased GI motility caused by metoclopramide may decrease cefprozil absorption
GI pH GI alkalinization by omeprazole may decrease absorption of ketoconazole
GI flora Decreased GI bacterial flora caused by antibiotic administration could decrease bacterial production of vitamin K, augmenting the anticoagulant effect of warfarin
6
Pharmacokinetic Drug InteractionsB. Distribution
Mechanism Examples
Displacement from plasma proteins
Displacement of methotrexate from plasma proteins by NSAIDs may increase risk of methotrexate toxicity
7
Pharmacokinetic Drug InteractionsC. Metabolism
•Enzymes associated with drug metabolism are called cytochrome P450 enzymes
• ‘’cytochrome’’ is derived from color of liver cells (dark red) attributed to iron content of the enzymes
•P450 refers to ultraviolet light wavelength absorbed by enzymes
8
Pharmacokinetic Drug InteractionsC. Metabolism•Cytochrome P450 nomenclatureCYP3A4
CYP Human cytochrome P4503 Family
A Subfamily4 Gene
•Enzymes belonging to the 3A and 2D subfamilies account for most of the well-identified drug interactions
9
Pharmacokinetic Drug InteractionsC. Metabolism
•Drugs that undergo hepatic biotransformation are frequently substrates for the same enzymes
•While requiring these enzymes for their own metabolism, they also may induce or inhibit enzyme activity on other drugs taken concurrently
10
Pharmacokinetic Drug InteractionsC. Metabolism
Mechanism Examples
Enzyme Inhibition Resulting in Increasing Risk of Toxicity
Inhibitors of CYP2C9 (e.g. amiodarone) can increase risk of toxicity from phenytoin, warfarin
Enzyme Inhibition Resulting in Reduced Drug Effect
Analgesic and toxic effects of codeine result from its conversion to morphine by CYP2D6.Thus, CYP2D6 inhibitors can impair therapeutic effect of codeine.
11
Pharmacokinetic Drug InteractionsC. Metabolism
Mechanism Examples
Enzyme Induction Resulting in Reduced Drug Effect
Examples of enzyme inducers include barbiturates, carbamazepine, phenytoin, rifampinSome drugs, e.g. ritonavir, may act as either an enzyme inhibitor or an enzyme inducer, depending on the situation
Enzyme Induction Resulting in Toxic Metabolites
A small amount of acetaminophen is converted to a cytototoxic metabolite Enzyme inducers can increase formation of toxic metabolite & increase risk of hepatotoxicity
12
Pharmacokinetic Drug InteractionsD. Elimination•Altered Renal Elimination
•For some drugs, active secretion into the renal tubules is an important route of elimination
•Example▫Digoxin is eliminated primarily through renal excretion, and
drugs such as amiodarone, clarithromycin, itraconazole can inhibit this process. Digoxin toxicity may result.
13
P-Glycoprotein•P-glycoprotein is a transporter found in the liver,
intestine, kidney, and brain
•P-glycoprotein acts as an efflux pump to pump toxic materials out of the cell
•Example▫Digoxin, a PGP substrate ▫Quinidine is a PGP inhibitor. It inhibits expulsion of digoxin
back into intestine, so increases digoxin concentrations ▫Rifampicin stimulates PGP and so decreases serum digoxin
14
P-Glycoprotein• In the kidney there is a similar effect with PGP enhancing
clearance of substances▫Quinidine and cyclosporine inhibit PGP, so clearance of
digoxin is inhibited
• In the CNS, PGP inhibits the passage of some medicines across the blood–brain barrier, e.g. loperamide ▫A PGP inhibitor allows greater passage across the blood–
brain barrier
15
Examples of P-glycoprotein Substrates/Inhibitors/InducersSubstrates Inhibitors InducersAmitriptyline Atorvastatin Azithromycin Carvedilol Colchicine Cyclosporine Dexamethasone Digoxin Erythromycin Ethinyl estradiol Glyburide
AmiodaroneClarithromycinCyclosporineDiltiazemErythromycinFelodipineIndinavirItraconazoleKetoconazoleNicardipineQuinidineRitonavirSirolimusTacrolimusVerapamil
RifampinCarbamazepine St. John’s wort
16
Pharmacodynamic Drug InteractionsA. Additive Pharmacodynamic Effects•When two or more drugs with similar pharmacodynamic
effects are given, additive effects may result in excessive response and toxicity
•Examples ▫Combining ACEI with potassium-sparing diuretics results in
augmented hyperkalemia
▫Combining a diuretic with a beta blocker provides a greater reduction in blood pressure than either can impart alone
17
Pharmacodynamic Drug InteractionsB. Antagonistic Pharmacodynamic Effects •Drugs with opposing pharmacodynamic effects may
reduce the response to one or both drugs
•Example▫NSAIDs may inhibit the antihypertensive effect of ACEI
Reduction in the synthesis of the vasodilating renal prostaglandins
18
Drug Interaction Risk Factors•Patient Factors▫Number of medications (polypharmacy)▫Severity of the diseases being treated▫Age (the very young and elderly)▫Renal and hepatic dysfunction▫Acute medical condition (eg, dehydration, infection)▫Pharmacogenetics
19
Drug Interaction Risk Factors•Drug Factors▫Higher dose▫Narrow therapeutic range (e.g.digoxin)▫NSAIDs▫Anticoagulants▫Hypoglycemics▫Antiarrythmics▫Anticonvulsants▫Antibiotics▫Antiretrovirals
20
Drug Interaction Risk Factors•Other Considerations▫Increasing use of prescription drugs▫Increasing complexity of medication regimens▫Fragmented health care system
Incomplete problem or med lists Multiple prescribers managing Multiple pharmacies dispensing Self-medication with OTC, herbals
21
Relevance of Drug Interactions• Impossible to memorize all drug interactions (2500 drug
pairs)
•Most potential drug interactions never lead to actual clinical effect
•Necessary to determine which drug interactions are most clinically important▫Ones most likely to cause harm if not detected
22
Drug Interaction Resources•Print & Electronic Resources▫Micromedex▫Lexicomp▫Facts and Comparisons▫Hansten and Horn’s The Top 100 Drug Interactions▫Stockley's Drug Interactions
•Websites▫Drug Interaction Checker (Medscape)▫Drug Interaction Checker (Drugs.com)
23
Managing Drug Interactions•Comprehensive medication review• Identify potential drug interactions•Assess clinical significance•Continue/discontinue/substitute•Monitor and follow-up•Document•Communicate with patient & healthcare professionals
24
Managing Drug InteractionsTips for Pharmacists• Learn to recognize factors that alter a patient’s risk for an
adverse event when exposed to interacting drug pairs
•Consider the risk of the potential interaction against the benefit of administering the drugs
• If the risk to patient appears to be greater than expected benefit, identify a suitable alternative
25
Managing Drug InteractionsTips for Pharmacists•Drug interaction classification systems should be used for
general guidance
•No book, PDA, or computer based classification system can replace pharmacist’s informed evaluation
•Regard each interaction– patient pair as unique
26
Case Study-1•A 23 y/o woman with a seizure disorder & diabetes is
being admitted with ataxia and tremors. She was initiated on Bactrim 10 days ago for UTI. Her Phenytoin level is 28. Her current medication list includes:
▫Sulfamethoxazole/trimethoprim DS 1 tab po BID▫Phenytoin 400 mg po QD▫Lantus 15 units SQ q HS▫Novolog 5 units SQ with each meal
•What actual drug-drug interaction(s) do you identify?• Could it have been prevented? What will you recommend?
27
Case Study-2•A 75 y/o woman with hypertension and atrial fibrillation
is prescribed levofloxacin for community acquired pneumonia. Her other medications include:▫ Sotalol 80 mg PO BID▫Aspirin 81 mg PO QD▫Enalapril 20 mg PO BID▫HCTZ 50 mg PO QD▫Felodipine 5mg PO QD
•What potential drug-drug interaction(s) do you identify?•What will you recommend?